{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:29:58Z","timestamp":1780392598040,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Estacio de Sa University"},{"DOI":"10.13039\/501100006507","name":"Funda\u00e7\u00e3o Oswaldo Cruz","doi-asserted-by":"publisher","award":["INI-003-FIO-19-2-5"],"award-info":[{"award-number":["INI-003-FIO-19-2-5"]}],"id":[{"id":"10.13039\/501100006507","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The role of liver stiffness measurement (LSM) after sustained virological response (SVR) in HCV patients treated by direct-acting antivirals (DAAs) remains unclear. We aimed to evaluate LSM regression value after SVR and to identify risk factors associated with liver related complications (LRC) or death. This retrospective study analyzed patients with LSM\u2009\u2265\u200910\u00a0kPa with LSM by transient elastography pre-DAAs and post-SVR. Patients with previous hepatic decompensation were excluded. Medical records were reviewed to identify primary outcomes. Kaplan\u2013Meier curves and time-to-event Cox proportional-hazard models were performed. 456 patients [65% female, 62\u00a0years (IQR 57\u201368)] were included. During a follow-up of 2.3\u00a0years (IQR 1.6\u20132.7), 28 patients developed 37 outcomes [rate\u2009=\u200929.0 (95% CI 20.0\u201342.0) per 1000 person-years]. The cumulative incidence of outcomes was significantly lower in patients who regressed LSM\u2009\u2265\u200920% [3.4% (95% CI 1.8\u20137.0) vs. 9.0% (5.5\u201314.5), p\u2009=\u20090.028]. In a multivariate Cox-model [HR(95% CI)], male gender [HR\u2009=\u20093.00 (1.30\u20136.95), p\u2009=\u20090.010], baseline albumin\u2009&lt;\u20093.5\u00a0mg\/dL [HR\u2009=\u20094.49 (1.95\u201310.34), p\u2009&lt;\u20090.001] and baseline unfavorable Baveno-VI [HR\u2009=\u20094.72 (1.32\u201316.83), p\u2009=\u20090.017] were independently associated and LSM regression\u2009\u2265\u200920% after SVR had a trend to reduce the risk of LRC or death [HR\u2009=\u20090.45 (0.21\u20131.02), p\u2009=\u20090.058]. The use of simple parameters before DAAs and repetition of LSM post-SVR can identify patients with different risks for severe outcome after HCV eradication.<\/jats:p>","DOI":"10.1038\/s41598-021-91099-1","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T10:15:03Z","timestamp":1622715303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes"],"prefix":"10.1038","volume":"11","author":[{"given":"Juliana","family":"Piedade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00edvia","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00edvia","family":"Victor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Baldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cintia","family":"Inacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00darsula","family":"Chaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estev\u00e3o P.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valdilea G.","family":"Veloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Perazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"91099_CR1","doi-asserted-by":"publisher","first-page":"12143","DOI":"10.1002\/14651858.CD012143.pub2","volume":"6","author":"JC Jakobsen","year":"2017","unstructured":"Jakobsen, J. C. et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst. Rev. 6, 12143. https:\/\/doi.org\/10.1002\/14651858.CD012143.pub2 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"91099_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.jceh.2018.07.004","volume":"9","author":"V Pecoraro","year":"2019","unstructured":"Pecoraro, V. et al. New direct-acting antivirals for the treatment of patients with hepatitis C virus infection: A systematic review of randomized controlled trials. J. Clin. Exp. Hepatol. 9(4), 522\u2013538. https:\/\/doi.org\/10.1016\/j.jceh.2018.07.004 (2019).","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"9","key":"91099_CR3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","volume":"166","author":"O Falade-Nwulia","year":"2017","unstructured":"Falade-Nwulia, O. et al. Oral direct-acting agent therapy for hepatitis c virus infection: A systematic review. Ann. Intern. Med. 166(9), 637\u2013648. https:\/\/doi.org\/10.7326\/M16-2575 (2017).","journal-title":"Ann. Intern. Med."},{"key":"91099_CR4","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 69(2),  461\u2013511 https:\/\/doi.org\/10.1016\/j.jhep.2018.03.026 (2018).","DOI":"10.1016\/j.jhep.2018.03.026"},{"issue":"2","key":"91099_CR5","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/hep.31060","volume":"71","author":"MG Ghany","year":"2020","unstructured":"Ghany, M. G., Morgan, T. R. & Panel A-IHCG. Hepatitis C guidance 2019 update: American Association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology 71(2), 686\u2013721. https:\/\/doi.org\/10.1002\/hep.31060 (2020).","journal-title":"Hepatology"},{"issue":"10179","key":"91099_CR6","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/s0140-6736(18)32111-1","volume":"393","author":"F Carrat","year":"2019","unstructured":"Carrat, F. et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 393(10179), 1453\u20131464. https:\/\/doi.org\/10.1016\/s0140-6736(18)32111-1 (2019).","journal-title":"Lancet"},{"issue":"5","key":"91099_CR7","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","volume":"157","author":"GN Ioannou","year":"2019","unstructured":"Ioannou, G. N. et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology 157(5), 1264\u20131278. https:\/\/doi.org\/10.1053\/j.gastro.2019.07.033 (2019).","journal-title":"Gastroenterology"},{"issue":"5","key":"91099_CR8","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/jvh.12846","volume":"25","author":"A Erman","year":"2018","unstructured":"Erman, A. et al. Estimating chronic hepatitis C prognosis using transient elastography-based liver stiffness: A systematic review and meta-analysis. J. Viral Hepat. 25(5), 502\u2013513. https:\/\/doi.org\/10.1111\/jvh.12846 (2018).","journal-title":"J. Viral Hepat."},{"issue":"7","key":"91099_CR9","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1053\/j.gastro.2011.02.058","volume":"140","author":"J Vergniol","year":"2011","unstructured":"Vergniol, J. et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 140(7), 1970\u20131979. https:\/\/doi.org\/10.1053\/j.gastro.2011.02.058 (2011).","journal-title":"Gastroenterology"},{"issue":"9","key":"91099_CR10","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.cgh.2019.04.062","volume":"17","author":"M Stafylidou","year":"2019","unstructured":"Stafylidou, M. et al. Performance of Baveno VI and expanded Baveno VI criteria for excluding high-risk varices in patients with chronic liver diseases: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 17(9), 1744\u20131755. https:\/\/doi.org\/10.1016\/j.cgh.2019.04.062 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"12","key":"91099_CR11","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1111\/jgh.14707","volume":"34","author":"FF Fernandes","year":"2019","unstructured":"Fernandes, F. F. et al. Effectiveness of direct-acting agents for hepatitis C and liver stiffness changing after sustained virological response. J. Gastroenterol. Hepatol. 34(12), 2187\u20132195. https:\/\/doi.org\/10.1111\/jgh.14707 (2019).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"91099_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cgh.2017.04.038","volume":"16","author":"S Singh","year":"2018","unstructured":"Singh, S., Facciorusso, A., Loomba, R. & Falck-Ytter, Y. T. Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: A systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 16(1), 27\u201338. https:\/\/doi.org\/10.1016\/j.cgh.2017.04.038 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"91099_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R de Franchis","year":"2015","unstructured":"de Franchis, R. & Baveno, V. I. F. Expanding consensus in portal hypertension: Report of the Baveno VI consensus workshop: Stratifying risk and individualizing care for portal hypertension. J. Hepatol. 63(3), 743\u2013752. https:\/\/doi.org\/10.1016\/j.jhep.2015.05.022 (2015).","journal-title":"J. Hepatol."},{"issue":"1","key":"91099_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12874-017-0332-6","volume":"17","author":"AN Kamarudin","year":"2017","unstructured":"Kamarudin, A. N., Cox, T. & Kolamunnage-Dona, R. Time-dependent ROC curve analysis in medical research: Current methods and applications. BMC Med. Res. Methodol. 17(1), 53. https:\/\/doi.org\/10.1186\/s12874-017-0332-6 (2017).","journal-title":"BMC Med. Res. Methodol."},{"issue":"19\u201320","key":"91099_CR15","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1111\/j.1365-2702.2011.04023.x","volume":"21","author":"R Flynn","year":"2012","unstructured":"Flynn, R. Survival analysis. J. Clin. Nurs. 21(19\u201320), 2789\u20132797. https:\/\/doi.org\/10.1111\/j.1365-2702.2011.04023.x (2012).","journal-title":"J. Clin. Nurs."},{"issue":"6","key":"91099_CR16","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1002\/hep.29707","volume":"67","author":"DK Li","year":"2018","unstructured":"Li, D. K. et al. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology 67(6), 2244\u20132253. https:\/\/doi.org\/10.1002\/hep.29707 (2018).","journal-title":"Hepatology"},{"key":"91099_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa702","author":"N Kronfli","year":"2020","unstructured":"Kronfli, N. et al. Liver fibrosis in human immunodeficiency virus (HIV)-hepatitis C virus (HCV) coinfection before and after sustained virologic response: What is the best noninvasive marker for monitoring regression?. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa702 (2020).","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"91099_CR18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jhep.2019.10.005","volume":"72","author":"M Pons","year":"2020","unstructured":"Pons, M. et al. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. J. Hepatol. 72(3), 472\u2013480. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.005 (2020).","journal-title":"J. Hepatol."},{"key":"91099_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1140","author":"A Corma-G\u00f3mez","year":"2019","unstructured":"Corma-G\u00f3mez, A. et al. Liver stiffness at the time of sustained virological response predicts the clinical outcome in people living with human immunodeficiency virus and hepatitis C virus with advanced fibrosis treated with direct-acting antivirals. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciz1140 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"91099_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31462","author":"G Semmler","year":"2020","unstructured":"Semmler, G. et al. Non-invasive risk stratification after HCV-eradication in patients with advanced chronic liver disease. Hepatology https:\/\/doi.org\/10.1002\/hep.31462 (2020).","journal-title":"Hepatology"},{"key":"91099_CR21","doi-asserted-by":"publisher","DOI":"10.1055\/a-1205-0367","author":"E Dajti","year":"2020","unstructured":"Dajti, E. et al. Spleen stiffness measurements predict the risk of hepatic decompensation after direct-acting antivirals in HCV cirrhotic patients. Ultraschall Med. https:\/\/doi.org\/10.1055\/a-1205-0367 (2020).","journal-title":"Ultraschall Med."},{"issue":"2","key":"91099_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","volume":"133","author":"C Ripoll","year":"2007","unstructured":"Ripoll, C. et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133(2), 481\u2013488. https:\/\/doi.org\/10.1053\/j.gastro.2007.05.024 (2007).","journal-title":"Gastroenterology"},{"issue":"6","key":"91099_CR23","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","volume":"73","author":"S Lens","year":"2020","unstructured":"Lens, S. et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J. Hepatol. 73(6), 1415\u20131424. https:\/\/doi.org\/10.1016\/j.jhep.2020.05.050 (2020).","journal-title":"J. Hepatol."},{"issue":"4","key":"91099_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","volume":"65","author":"M Mandorfer","year":"2016","unstructured":"Mandorfer, M. et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J. Hepatol. 65(4), 692\u2013699. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.027 (2016).","journal-title":"J. Hepatol."},{"issue":"4","key":"91099_CR25","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1053\/j.gastro.2018.11.053","volume":"156","author":"D Thabut","year":"2019","unstructured":"Thabut, D. et al. Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy. Gastroenterology 156(4), 997\u20131009. https:\/\/doi.org\/10.1053\/j.gastro.2018.11.053 (2019).","journal-title":"Gastroenterology"},{"issue":"8","key":"91099_CR26","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/liv.12240","volume":"33","author":"S Bota","year":"2013","unstructured":"Bota, S. et al. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int. 33(8), 1138\u20131147. https:\/\/doi.org\/10.1111\/liv.12240 (2013).","journal-title":"Liver Int."},{"issue":"1","key":"91099_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","volume":"63","author":"European Association for Study of L","year":"2015","unstructured":"European Association for Study of L & Asociacion Latinoamericana para el Estudio del H. Asociacion Latinoamericana para el Estudio del H EASL-ALEH clinical practice guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol. 63(1), 237\u2013264. https:\/\/doi.org\/10.1016\/j.jhep.2015.04.006 (2015).","journal-title":"J. Hepatol."},{"issue":"5","key":"91099_CR28","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1111\/liv.12551","volume":"35","author":"H Perazzo","year":"2015","unstructured":"Perazzo, H. et al. Interobserver variability in transient elastography analysis of patients with chronic hepatitis C. Liver Int. 35(5), 1533\u20131539. https:\/\/doi.org\/10.1111\/liv.12551 (2015).","journal-title":"Liver Int."},{"issue":"1","key":"91099_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/jum.14856","volume":"38","author":"G Ferraioli","year":"2019","unstructured":"Ferraioli, G. Review of liver elastography guidelines. J. Ultrasound Med. 38(1), 9\u201314. https:\/\/doi.org\/10.1002\/jum.14856 (2019).","journal-title":"J. Ultrasound Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91099-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91099-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91099-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T09:19:41Z","timestamp":1670059181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91099-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["91099"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-91099-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"20 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11681"}}